Marshall Wace
ONCY

Marshall Wace’s Oncolytics Biotech ONCY Stock Holding History

Marshall Wace’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$708K Sell
745,350
-114,481
-13% -$106K ﹤0.01% 2360
2026
Q1 		$731K Buy
859,831
+597,661
+228% +$594K ﹤0.01% 2284
2025
Q4 		$228K Sell
262,170
-61,812
-19% -$66.8K ﹤0.01% 2555
2025
Q3 		$454K Buy
+323,982
New +$363K ﹤0.01% 2268
2021
Q1 		– Sell
-112,594
Closed -$268K – 2756
2020
Q4 		$268K Buy
+112,594
New +$270K ﹤0.01% 1680

Other funds holding ONCY

XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SI
Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Marshall Wace's ONCY Position: Q2 2026 in Review

Marshall Wace reduced its Oncolytics Biotech (ONCY) stake by 13% in Q2 2026, selling an estimated $106K and leaving 745,350 shares worth $708K. The position accounts for ﹤0.01% of the portfolio, ranked #2360.

Marshall Wace first reported a position in ONCY in Q4 2020 and has held it in 5 quarters since. The position peaked at $731K in Q1 2026. 75 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • Marshall Wace held 745,350 shares of Oncolytics Biotech worth $708K as of Q2 2026.
  • Marshall Wace sold 114,481 Oncolytics Biotech shares in Q2 2026, an estimated $106K.
  • Oncolytics Biotech made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2360 holding.
  • Marshall Wace first reported a position in Oncolytics Biotech in Q4 2020 and has held it in 5 quarters since.
  • Marshall Wace's Oncolytics Biotech position peaked at $731K in Q1 2026.
  • 75 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.